|
| The extended 4year followup results of the ELOQUENT2 trial |
|
https://doi.org/10.18632/oncotarget.26527
Maria Gavriatopoulou, Evangelos Terpos, and Meletios Athanasios Dimopoulos
|
| 82-83 |
|
| We shall overcome drug resistance some day |
|
https://doi.org/10.18632/oncotarget.26550
Geeta G. Sharma, and Luca Mologni
|
| 84-85 |
|
| AI for medical use |
|
https://doi.org/10.18632/oncotarget.26556
Masamitsu Konno, and Hideshi Ishii
|
| 86-87 |
|
| Association between thyroid function and diabetic nephropathy in euthyroid subjects with type 2 diabetes mellitus: a crosssectional study in China |
|
https://doi.org/10.18632/oncotarget.26265
Jian Wang, Huiqin Li, Mingjuan Tan, Gu Gao, Ying Zhang, Bo Ding, Xiaofei Su, Xiaocen Kong, and Jianhua Ma
|
| 88-97 |
|
| Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP1 and TIMP2 |
|
https://doi.org/10.18632/oncotarget.26414
J. Dinesh Kumar, Iman Aolymat, Laszlo Tiszlavicz, Zita Reisz, Hanan M. Garalla, Rob Beynon, Deborah Simpson, Graham J. Dockray, and Andrea Varro
|
| 98-112 |
|
| Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies |
|
https://doi.org/10.18632/oncotarget.26451
Ashleigh C. McEvoy, Michelle R. Pereira, Anna Reid, Robert Pearce, Lester Cowell, Zeyad Al-Ogaili, Muhammad A. Khattak, Michael Millward, Tarek M. Meniawy, Elin S. Gray, and Melanie Ziman
|
| 113-122 |
|
| RASSF1C regulates miR33a and EMT marker gene expression in lung cancer cells |
|
https://doi.org/10.18632/oncotarget.26498
Yousef G. Amaar, and Mark E. Reeves
|
| 123-132 |
|
| Implication of calcium activated RasGRF2 in Annexin A6mediated breast tumor cell growth and motility |
|
https://doi.org/10.18632/oncotarget.26512
Diva S. Whalen, Sarrah E. Widatalla, Olga Y. Korolkova, Gladys S. Nangami, Heather K. Beasley, Stephen D. Williams, Carlos Virgous, Brian D. Lehmann, Josiah Ochieng, and Amos M. Sakwe
|
| 133-151 |
|
| Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers |
|
https://doi.org/10.18632/oncotarget.26520
Jyoti Roy, Miranda Kaake, and Philip S. Low
|
| 152-160 |
|
| Lowdose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo |
|
https://doi.org/10.18632/oncotarget.26536
Kenta Watanabe, Yoshihiro Yui, Satoru Sasagawa, Kayo Suzuki, Masahiko Kanamori, Taketoshi Yasuda, and Tomoatsu Kimura
|
| 161-174 |
|
| Photoimmune therapy with liposomally formulated phospholipidconjugated indocyanine green induces specific antitumor responses with heat shock protein70 expression in a glioblastoma model |
|
https://doi.org/10.18632/oncotarget.26544
Sayaka Shibata, Natsuki Shinozaki, Akiko Suganami, Shiro Ikegami, Yuki Kinoshita, Ryozo Hasegawa, Hirata Kentaro, Yoshiharu Okamoto, Ichio Aoki, Yutaka Tamura, and Yasuo Iwadate
|
| 175-183 |
|
| Failures in preclinical and clinical trials of cMet inhibitors: evaluation of pathway activity as a promising selection criterion |
|
https://doi.org/10.18632/oncotarget.26546
Veronica S. Hughes, and Dietmar W. Siemann
|
| 184-197 |
|
| Molecular subtypes of triplenegative breast cancer in women of different race and ethnicity |
|
https://doi.org/10.18632/oncotarget.26559
Yuan Chun Ding, Linda Steele, Charles Warden, Sharon Wilczynski, Joanne Mortimer, Yuan Yuan, and Susan L. Neuhausen
|
| 198-208 |
|
| Immune checkpoint inhibitors in EGFRmutation positive TKItreated patients with advanced nonsmallcell lung cancer network metaanalysis |
|
https://doi.org/10.18632/oncotarget.26541
Luigi Cavanna, Chiara Citterio, and Elena Orlandi
|
| 209-215 |
|
| Circulating mediators of remote ischemic preconditioning: search for the missing link between nonlethal ischemia and cardioprotection |
|
https://doi.org/10.18632/oncotarget.26537
Muntasir Billah, Anisyah Ridiandries, Usaid Allahwala, Harshini Mudaliar, Anthony Dona, Stephen Hunyor, Levon M. Khachigian, and Ravinay Bhindi
|
| 216-244 |
|
| ROS1GOPC/FIG: a novel gene fusion in hepatic angiosarcoma |
|
https://doi.org/10.18632/oncotarget.26521
Eric I. Marks, Sahithi Pamarthy, Don Dizon, Ari Birnbaum, Evgeny Yakirevich, Howard Safran, and Benedito A. Carneiro
|
| 245-251 |
|
| Correction: Clinical characteristics and prognoses of patients treated surgically for metastatic lung tumors |
|
https://doi.org/10.18632/oncotarget.26575
Xiaoliang Zhao, Xiaohua Wen, Wei Wei, Yulong Chen, Jianquan Zhu, and Changli Wang
|
| 252-252 |
|
| Correction: Incidence and risk of regorafenibinduced hepatotoxicity |
|
https://doi.org/10.18632/oncotarget.26576
Bin Zhao, and Hong Zhao
|
| 253-253 |
|
| Correction: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib |
|
https://doi.org/10.18632/oncotarget.26577
Bin Zhao, and Hong Zhao
|
| 254-254 |
